Branham Law, LLP Investigates AMAG Pharmaceuticals on Behalf of Stockholders
DALLAS -- February 11, 2013
Branham Law, LLP announces that it is investigating AMAG Pharmaceuticals
(NASDAQ: AMAG) and certain of its officers and directors for potential
breaches of fiduciary duties in connection with AMAG’s apparent failure to
disclose that users of the Company’s primary drug, Feraheme had suffered
adverse reactions, including hospitalizations and one possible death.
Investors who purchased AMAG stock before January 1, 2010 and have held AMAG
stock since, or anyone with information about this investigation should
contact Branham Law, LLP at firstname.lastname@example.org or call (855) 722-5910.
On February 4, 2013, the United States First Circuit Court of Appeals reversed
the district court’s dismissal of these claims and reinstated the action.
After these failures to disclose were revealed, AMAG’s stock fell over $7.00
per share. Subsequent disclosures regarding the company’s rebate program
resulted in a further drop of $4.02 per share.
Contact Trey Branham, Branham Law, LLP, 1-855-722-5910, 3900 Elm Street,
Dallas, Texas 75226 for additional information.
Branham Law, LLP
Trey Branham, 214-722-5990
Press spacebar to pause and continue. Press esc to stop.